Effect of particle size on the oral absorption of isoliquiritigenin nanocrystals
DOI:
https://doi.org/10.1590/s2175-97902022e201186Keywords:
Isoliquiritigenin, Nanocrystals, Particle size, Oral bioavailability, HPLC-MS/MSAbstract
As one of the most promising formulations for poorly water-soluble drugs, nanocrystals have been attracting increasing attention in recent years. Isoliquiritigenin (ISL) is a flavonoid with a chalcone structure, and possesses many biological activities. However, its clinical application is significantly limited mainly due to its low oral bioavailability caused by poor hydrophilicity. To address this, ISL nanocrystals were developed in this study to improve its oral bioavailability. Three types of nanocrystals with differing particle size; R1, R2, and R3, were prepared by anti- solvent precipitation or anti-solvent precipitation combined with sonication, which was optimized by single-factor experiments. These nanocrystals were characterized based on their physical properties, in vitro release, and in vivo absorption performance. The mean particle size of R1, R2, and R3 was 555.7, 271.0, and 46.2, respectively. The dissolution ratio of ISL in the nanocrystals was significantly improved, with the quickest rate recorded in R2. Peak concentration and area under the concentration-time curve of R2 after oral administration in rats was 5.83- and 2.72-fold higher than that of the ISL solution, respectively. These findings indicate that the dissolution and absorption of ISL can be significantly enhanced by nanocrystals, and the dissolution behavior and pharmacokinetic properties of nanocrystals is significantly influenced by particle size.
Downloads
References
Chang DC, Ma YN, Cao GY, Wang JH, Zhang X, Feng J, et al. Improved oral bioavailability for lutein by nanocrystal technology: formulation development, in vitro and in vivo evaluation. Artif Cells Nanomed Biotechnol. 2018;46(5):1018- 1024.
Gan MY, Zhang WP, Wei SJ, Dang HW. The influence of mPEG-PCL and mPEG-PLGA on encapsulation efficiency and drug-loading of SN-38NPs. Artif Cells Nanomed Biotechnol . 2017;45(2):389-397.
Gao L, Liu GY, Ma JL, Wang XQ, Zhou L, Li X, et al. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharm Res. 2013;30(2):307- 24.
Gol D, Thakkar S, Misra M. Nanocrystal-based drug delivery system of risperidone: lyophilization and characterization. Drug Dev Ind Pharm. 2018;44(9):1458-1466.
Hong JY, Liu YY, Xiao Y, Yang XF, Su WJ, Zhang MZ, et al. High drug payload curcumin nanosuspensionsstabilized by mPEG-DSPE and SPC: in vitro and in vivo evaluation. Drug Deliv. 2017;24(1):109-120.
Hsu YL, Kuo PL, Lin CC. Isoliquiritigenin induces apoptosis and cell cyclearrest through p53-dependent pathway in Hep G2 cells. Life Sci. 2005;77(3):279-92.
Jung SK, Lee MH, Lim DY, Kim JE, Singh P, Lee SY, et al. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR. J Biol Chem. 2014;289(52):35839-48.
Kanazawa M, Satomi Y, Mizutani Y, Ukimura O, Kawauchi A, Sakai T, et al. Isoliquiritigenin inhibits the growth of prostate cancer. Eur Urol. 2003;43(5):580-6.
Kobayashi S, Miyamoto T, Kimura I, Kimura M. Inhibitory effect of isoliquiritigenin, a compound in licorice root, onangiogenesis in vivo and tube formation in vitro. Biol Pharm Bull. 1995;18(10):1382-6.
Kwon GT, Cho HJ, Chung WY, Park KK, Moon A, Park JHY. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. Biofactors. J Nutr Biochem. 2009;20(9):663-76.
Lee SK, Park KK, Kim KR, Kim HJ, Chung WY. Isoliquiritigenin inhibits metastatic breast cancer cell- induced receptor activator of nuclear factor kappa-B ligand/ osteoprotegerin ratio in human osteoblastic cells. J Cancer Prev. 2015;20(4):281-6.
Lee YK, Chin YW, Bae JK, Seo JS, Choi YH. Pharmacokinetics of isoliquiritigenin and its metabolites in rats: low bioavailability is primarilydue to the hepatic and intestinal metabolism. Planta Med. 2013;79(17):1656-65.
Liu Y, Lin T, Cheng C, Wang Q, Lin S, Liu C, et al. Research Progress on Synthesis and Application of Cyclodextrin Polymers. Molecules. 2021a;26(4):1090.
Liu Z, Hu M, Zhang S, Jiang L, Xie F, Li Y. Oil-in-water Pickering emulsion stabilization with oppositely charged polysaccharide particles: chitin nanocrystals/fucoidan complexes. J Sci Food Agric. 2021b;101(7):3003-3012.
Pardhi VP, Verma T, Flora SJS, Chandasana H, Shukla R. Nanocrystals:an overview of fabrication,characterization and therapeutic applications in drug delivery. Curr Pharm Des. 2018;24(43):5129-5146.
Park I, Park KK, Park JHY, Chung WY. Isoliquiritigenin induces G2 and M phase arrest by inducing DNA damage and by inhibiting the metaphase/anaphase transition. Cancer Lett. 2009;277(2):174-81.
Patel D, Zode SS, Bansal AK. Formulation aspects of intravenous nanosuspensions. Int J Pharm. 2020;586:119555.
Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promisingdrug delivery strategy. J Pharm Pharmacol. 2004;56(7):827-40.
Peng F, Qiaohui D, Cheng P, Wang N, Tang H, Xie X, et al. A review: the pharmacology of isoliquiritigenin. Phytother Res. 2015;29(7):969-77.
Tuomela A, Hirvonen J, Peltonen L. Stabilizing Agents for Drug Nanocrystals: Effect on Bioavailability. Pharmaceutics. 2016;8(2):16.
Wang JR, Luo YH, Piao XJ, Zhang Y, Feng YC, Li JQ, et al. Mechanisms underlying isoliquiritigenin-induced apoptosis and cell cycle arrest via ROS-mediated MAPK/STAT3/NF- κB pathways in human hepatocellular carcinoma cells. Drug Dev Res. 2019;80(4):461-470.
Wu CH, Chen HY, Wang CW, Shieh TM, Huang TC, Lin LC, et al. Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice. Oncotarget. 2016;7(45):73432-73447.
Yang H, Kim H, Jung S, Seo H, Nida SK, Yoo SY, et al. Pharmaceutical Strategies for Stabilizing Drug Nanocrystals. Curr Pharm Des . 2018; 24(21):2362-2374.
Yoshida T, Horinaka M, Takara M, Tsuchihashi M, Mukai N, Wakada M, et al. Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells. Environ Health Prev Med. 2008;13(5):281-7.
Zhang XR, Wang SY, Sun W, Wei C. Isoliquiritigenin inhibits proliferation and metastasis of MKN28 gastric cancer cells by suppressing the PI3K/AKT/mTOR signaling pathway. Mol Med Rep. 2018;18(3):3429-3436.
Zhang XY, Qiao H, Ni JM, Shi YB, Qiang Y. Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice. Eur J Pharm Sci. 2013;49(3):411-422.
Zhang Y, Zhang R, Ni HJ. Eriodictyol exerts potent anticancer activity against A549 human lung cancer cell line by inducing mitochondrial-mediated apoptosis, G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signalling pathway. Arch Med Sci. 2019;16(2):446-452.
Zhou JX, Wink M. Evidence for anti-inflammatory activity of isoliquiritigenin, 18β glycyrrhetinic acid, ursolic acid, and the traditional chinese medicine plants glycyrrhiza glabra and eriobotrya japonica, at the molecular level. Medicines. 2019;6(2):55.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
